The United Laboratories International Holdings Limited

HKSE 3933.HK

The United Laboratories International Holdings Limited EPS (Diluted) for the year ending December 31, 2023: USD 0.21

The United Laboratories International Holdings Limited EPS (Diluted) is USD 0.21 for the year ending December 31, 2023, a 66.47% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

The United Laboratories International Holdings Limited EPS (Diluted) for the year ending December 31, 2022 was USD 0.13, a 48.35% change year over year.
The United Laboratories International Holdings Limited EPS (Diluted) for the year ending December 31, 2021 was USD 0.08, a 38.68% change year over year.
The United Laboratories International Holdings Limited EPS (Diluted) for the year ending December 31, 2020 was USD 0.06, a 9.42% change year over year.
The United Laboratories International Holdings Limited EPS (Diluted) for the year ending December 31, 2019 was USD 0.06, a 4.10% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

HKSE: 3933.HK

The United Laboratories International Holdings Limited

CEO	Mr. Hoi Shan Tsoi
IPO Date	June 15, 2007
Location	Hong Kong
Headquarters	6 Fuk Wang Street
Employees	15,000
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care Plastics

Description

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Key trends

Past 5 years